CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
modafinil 50mg +1 moredrug
Likely dose
modafinil 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03083132
NCT03083132Phase 2Completed
CompareCT.gov

Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's Disease

University of Arkansas·interventional·Posted Mar 17, 2017·Updated Oct 27, 2021

In Brief

A Phase 2 clinical trial evaluating modafinil 50mg and Placebo oral capsule for Parkinson Disease. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Freezing of gait is a late stage complication of Parkinson's disease in which patients note that their feet feel stuck or glued to the ground. This can lead to imbalance and falls and the secondary complications that can result from falls such as fractures and hospitalizations. While levodopa can help freezing of gait in some patients, it does not help in all, and the dose needed to treat freezing may be limited by side effects of the medications. Currently there are no treatments targeted towards freezing of gait and the goal of this research is to see if Modafinil could be one such drug to help freezing of gait in Parkinson's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 17, 2017
Enrollment StartJun 13, 2017
Primary CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.3 years ago

Interventions

modafinil 50mgdrug

1 capsule oral daily

Placebo oral capsuledrug

1 capsule oral daily